SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
8,81 USD
arrow_upward
+1,50%(+0,13) 1 D.
10-13, 16:00:00 GMT−4 · USD
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „SGIOY“ įžvalgos...
Atidaryti
8,66 USD
Aukšta
8,85 USD
Žema
8,66 USD
Rinkos kapitalizacija
2,50 trln.
Vid. kiekis
169,23 tūkst.
Apimtis
118,89 tūkst.
52 sav. aukšta
12,00 USD
52 sav. žema
7,65 USD
Beta
0,07
Neapmokėtos akcijos
1,78 mlrd.
Darbuotojų skaičius
6 tūkst.
Atidaryti
8,66 USD
Aukšta
8,85 USD
Žema
8,66 USD
Rinkos kapitalizacija
2,50 trln.
Vid. kiekis
169,23 tūkst.
Apimtis
118,89 tūkst.
52 sav. aukšta
12,00 USD
52 sav. žema
7,65 USD
Beta
0,07
Neapmokėtos akcijos
1,78 mlrd.
Darbuotojų skaičius
6 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
vz.lt
·
prieš 1 dieną
JAV rinkų apžvalga: prieš rezultatų skelbimo sezoną Volstrite nuotaikos nevienodos
MarketBeat
·
prieš 19 minučių
EverQuote (NASDAQ:EVER) Director Sells 1,593 Shares of Stock
01net
·
prieš 25 minutes
Five9 Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
The Globe and Mail
·
prieš 1 valandą
Kaplan Fox Urges AST SpaceMobile, Inc. (NASDAQ: ASTS) Investors to Contact the Firm Before the Deadline on November 13, 2026
Profilis
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
Apie „Shionogi 2 ADR Representing 1 Ord Shs“
Generalinis direktoriusIsao Teshirogi
Darbuotojai6,22 tūkst.
Įkurta1878
Pagrindinė būstinė-
Sektorius-
Svetainėshionogi.com